17:30 Fri 17 Apr 2020
Adv Medical Soln Grp - Director/PDMR Shareholding
|
|
Advanced Medical Solutions Group plc
("AMS", the "Company" or the "Group")
Director/PDMR Shareholding
Director/PDMR |
Options prior to grant |
Options granted |
Resultant LTIP holdings |
Chief Executive Officer |
629,517
|
254,812
|
884,329
|
Chief Financial Officer |
138,126
|
72,197
|
210,323
|
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. |
Details of the person discharging managerial responsibilities/person closely associated |
||||
a) |
|
||||
2. |
Reason for the notification |
||||
a) |
Position/status: Director/PDMR |
||||
b) |
Initial notification/Amendment: Initial Notification |
||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
|
||||
b) |
LEI: 213800HJP6OWOSZI1L74 |
||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
a) |
Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 |
||||
b) |
Nature of the transactions: · Grant of 254,812 options under the Advanced Medical Solutions Long Term Incentive Plan on |
||||
c) |
Price(s) and volume(s):
|
||||
d) |
Aggregated information: Aggregated volume: n/a Aggregated price: n/a |
||||
e) |
Date of the transaction: |
||||
f) |
Place of the transaction: |
1. |
Details of the person discharging managerial responsibilities/person closely associated |
||||
a) |
|
||||
2. |
Reason for the notification |
||||
a) |
Position/status: Director/PDMR |
||||
b) |
Initial notification/Amendment: Initial Notification |
||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
|
||||
b) |
LEI: 213800HJP6OWOSZI1L74 |
||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
a) |
Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 |
||||
b) |
Nature of the transactions: · Grant of 72,197 options under the Advanced Medical Solutions Long Term Incentive Plan on |
||||
c) |
Price(s) and volume(s):
|
||||
d) |
Aggregated information: Aggregated volume: n/a Aggregated price: n/a |
||||
e) |
Date of the transaction: |
||||
f) |
Place of the transaction: |
-End -
For further information, please contact:
|
Tel: +44 (0) 1606 545508 |
|
|
|
|
|
Tel: +44 (0) 20 3709 5700 |
|
|
|
|
|
Tel: +44 (0) 20 7597 5970 |
|
|
About
AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and wound care markets, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, and internal fixation devices, which it markets under its brands LiquiBand®, RESORBA®, and LiquiBand® Fix8TM. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. In 2019, the Group made two acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; and Biomatlante, an established developer and manufacturer of innovative surgical biomaterial technologies based in
AMS's products, manufactured in the
This information is provided by RNS, the news service of the
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE